Skip to main content | ne) tablets 10 mg

SAVINGS & SUPPORT **Getting Started With MAVENCLAD** 

Download, print, or email professional resources about MAVENCLAD and treating relapsing multiple sclerosis (RMS).

ePrescribe at MS LifeLines Pro™

Manage your patients on their MS treatment journey with MAVENCLAD

Mechanism of Action V Patient Types Clinical Efficacy V Safety & Tolerability Dosing & Monitoring V Savings & Support V

Through the MS LifeLines Pro portal, you can start a patient prescription, sign up to receive alerts, send messages to the MS LifeLines team, and more. To register, visit the portal online by clicking the button below or call 1-877-447-3243.

REGISTER AT MS LIFELINES PRO™ ☑

In addition to MS LifeLines Pro portal, there are other options to help initiate and manage prescriptions. Visit IAssist and CoverMyMeds to explore additional




Service Request Form

You can prescribe MAVENCLAD using a Service Request Form. Just print it, fill it out, and fax it to 1-866-227-3243 to get started. Completing this form with your patient also gives them the ability to sign up for one-on-one support services provided by MS LifeLines".

Questions about filling out the Service Request Form?

GET INSTRUCTIONS HERE &



Treatment Initiation Considerations

View the treatment initiation considerations for helpful information to take into account prior to prescribing MAVENCLAD for your patients.

Dosing Guide

Learn about weight-based dosing and convenient MAVENCLAD packaging.

INDICATION and IMPORTANT SAFETY INFORMATION for MAVENCLAD" (cladribine) tablets

MAVENCLAD\* (cladribine) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to

treatment of MS. MAVENCLAD Limitotions of Use: MAVENCLAD is not recommended for use in patients with clinically alated syndrome (CIS) because of its safety profile. MAVENCIAD is the first and on proven efficacy over W seeks of 20 days of real treatment.15

ATT CONTRACTOR SEC

MAVENCLAD\* (cladribine) tablets

MAVENCLAD\* (cladribine) is indicated for the treatment of relapsing forms of multiple

sclerosis (MS), to include relapsing-remitting

recommended for patients who have had an

disease and active secondary progressive

disease, in adults. Because of its safety

profile, use of MAVENCLAD is generally

inadequate response to, or are unable to

Limitations of Use: MAVENCLAD is not

recommended for use in patients with

its safety profile.

tolerate, an alternate drug indicated for the

clinically isolated syndrome (CIS) because of

IMPORTANT SAFETY INFORMATION WARNING: MALIGNANCIES and RISK OF TERATOGENICITY

 Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of MAVENCLAD on an individual patient basis. Follow standard cancer screening guidelines in patients treated with MAVENCLAD. · MAVENCLAD is contraindicated for use in pregnant women and in women and men of

0

reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with MAVENCLAD in females of reproductive Getting Your Patients Regay for Year 2 potential. Advise females and males of reproductive potential to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course. Stop MAVENCLAD if the patient becomes pregnant. treatment with MAVENCLAD. CONTRAINDICATIONS

Patients with current malignancy.

. Pregnant women, and women and men of reproductive potential who do not plan to use effective contraception during and for 6 months after the last dose in each treatment course. May cause fetal harm.


Patients infected with human immunodeficiency virus (HIV).

· Patients with active chronic infections (e.g., hepatitis or tuberculosis). Patients with a history of hypersensitivity to cladribine.

. Women intending to breastfeed on a MAVENCLAD treatment day and for 10 days after the last

AND PRECAUTIONS ies: Treatment with INVESTILL COUSE STATE OF MODERNING, After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during t 2 years. In canical statistics (Statistics Wild MayENGLA Banding) statistical treatment viting 2 years after the first 2년(2년(학교 대전 All Della State Complete State Completion of 2 See maligned by with reinit 한다양 MAVENCLAD more than 2 years after the completion of 2 tment courses has not been studied. Follow standard cancer screening guidelines in colents treated with MAVENCLAD.

 Risk of Teratogenicity: MAVENCLAD may cause fetal harm when administered to pregnant wamen. In females of reproductive potential, exclude pregnancy before initiation of each treatment course of MAVENCLAD and prevent by the use of effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose of each treatment course. Women who become pregnant during treatment with MAVENCLAD should discontinue



Screen patients for active and latent infections (tuberculosis, hepatitis B or C). Delay treatment until infection is fully resolved or controlled.

osis and fulminant hepatitis B were reported in the clinical program.

Vaccinate patients who are seronegative for varicella zoster virus (VZV) prior to treatment. Vaccinate patients who are seropositive to VZV with recombinant, adjuvanted zoster vaccine either prior to or during treatment, including when their lymphocyte counts are less than or equal to 500 cells per microliter

 Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells IMPORTANT SAFETY INFORMATION INDICATION and IMPORTANT SAFETY INFORMATION for

Progressive multifocal leukoencephalopathy (PML) has been reported in patients treated WARNING: MALIGNANGIES and RISIG OF TERRATIO GENIGITORs. No case of PML has been reported in

 Treatfileira with that encladed in the property of the property o contribution (49%) pithing want built franchisting the franchist want only read (40%) After increditation for the manufactory in the bold of the bold of the standard of t individual patient basis. Frobbiens dendards concerns feels (2) galderlines to patients attituded with MAVENCEADLes prior to starting MAVENCLAD. Administer live-attenuated or live vaccines at · MAVENCE ACT'S CONTROLLED TO TUSE MAYENGER WHITE WARREN and The Warrier and men of

Reproadolatigie (flatierittijal rwholdborrotoplymatioapserét/extrive coet riocethéobil beclassie afritie

betention for detail harreteMolfpreription separatembritis IMA/GENCA-ADvined inconstruction Excloration pregnets jobsforecthet \$GBCbfvitectiffent with MAVENG LABbindeybelesurfrepfoductideluring petential: Askriszifealigleismediteglendiseerodinitieë-potëntiakto use effective contraception dvina MAVENGJA Didago and the 6 method for the last described to entropy course. Step MAYENCIAD if the patient heremented the following the representation of nonirradiated blood in patients treated

CONTRAINGICATED REPORT OF THE PROPERTY OF THE irradiation of cellular blood components is recommended.

• Patients with current malignancy.

Patients with current malignancy.
 Liver Injury: In clinical studies, 0.3% of MAVENCLAD-treated patients had liver injury (serious or Pregnant women, and women and, men of reproductive potential who do not plan to use causing treatment discontinuation) compared to 0 placebo potents. Obtain serum effective contraception during and for 6 months offer the last dose in each treatment course, aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment.

May cause fetal harm.
Discontinue MAVENCLAD if clinically significant liver injury is suspected. Patients infected with human immunodeficiency virus (HIV).
 Hypersensitivity: If a hypersensitivity reaction is suspected, discontinue MAVENCLAD therapy.

 Bothsofeselin avene carringlefestions in a histogram gotelpers vingle to cladribine. · \* Cationals Pathurs historicate in the Pathurs has been stilled to the Prediction of the Pathurs historical life-Wornderling-risking recipiese fleiedrow is Mak/EMCELAB, switch hierardug clinis to click doctors the lytherics.

treatment indications other than multiple sclerosis. Instruct patients to seek medical advice if WARNINGS AND PRECAUTIONS. They experience symptoms of cardiac failure (e.g., shortness of breath, rapid or irregular \* Medianeacies/diregment with MAVENCLAD may increase the risk of malignancy. After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during Advase Registers. The inner secure, palverse mestical les deares à l'Alvene Laber estricator tractioning ignahearder the find which have courses had an increased incidence of malignancy. The

week. Cases of cardiac failure have also been reported with parenteral cladribine used for

Drugstintermethansings ind binnethint laties and AVENGLAB uppressive of vegets attacked received and service and s immtendment naturyes high tiest in manufacturistic follows treatment and an included in the contract of ad IBMSENSASTRA AND MANGENGAR MANGENGAR with corticosteroids can be administered. Monitor for odditiseur fferdrugs therityr matrifrede aborefie cuitieure, of itempotentia diseas. Anniel peneargitant use of qualivisal an elementaryleal sisuaxive yolder concentrate and find a find the initial assess they manetenlein costine is the ANGUAD-ANd prevent by the use of effective contraception during MAYENCLAD dosing and for at least 6 months after the last dose of each treatment course. Women who become pregnant during treatment with MAVENCLAD should discontinue years, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic

• Lymphopenia: MAVENCLAD causes a dose-dependent reduction in lymphocyte count.
To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono, Inc. at 1-800-283-8088 ext. 5563 on Contact that use of MAVENCLAD with hematotoxic drugs may increase the risk of adverse or FDA at 1-800-FDA-1088 or www.fda.agov/medwatch, reactions because of the adultive hematological effects. Monitor lymphocyte counts before,

impairment is not recommended.

Plesisting TOP PRESURE THE SURFERING INFORMATION, including BOXED WARNING. Infections: Serious, including life-threatening or fatal, infections have occurred. MAVENCLAD reduces the body's immune defense, and an increased risk of infections has been observed in patients receiving MAVENCLAD. Infections occurred in 49% of MAVENCLAD-treated patients compared to 44% of patients treated with placebo in clinical studies; serious or severe

infections occurred in 2.4% of MAVENCLAD- treated patients and 2.0% of placebo-treated patients. The most frequent serious infections included herpes zoster and pyelonephritis. Fungal infections were observed, including cases of coccidioidomycosis. Single fatal cases of tuberculosis and fulminant hepatitis B were reported in the clinical program. Screen patients for active and latent infections (tuberculosis, hepatitis B or C). Delay

treatment until infection is fully resolved or controlled.

 Vaccinate patients who are seronegative for varicella zoster virus (VZV) prior to treatment. Vaccinate patients who are seropositive to VZV with recombinant, adjuvanted zoster vaccine either prior to or during treatment, including when their lymphocyte counts are less than or equal to 500 cells per microliter.

 Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter. Monitor for infections.

 Progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with parenteral cladribine for ancologic indications. No case of PML has been reported in clinical studies of cladribine in patients with MS. Obtain a baseline magnetic resonance imaging (MRI) within 3 months before initiating the first treatment course of MAVENCLAD.

At the first sign of PML, withhold MAVENCLAD and perform an evaluation. Administer all immunizations (except as noted for VZV) according to immunization guidelines prior to starting MAVENCLAD. Administer live-attenuated or live vaccines at

least 4 to 6 weeks prior to starting MAVENCLAD due to risk of infection \* Hematologic Toxicity: In addition to lymphopenia, decreases in other blood cells and hematological parameters have been reported with MAVENCLAD in clinical studies. Obtain complete blood count (CBC) with differential including lymphocyte count before and during

treatment, periodically thereafter, and when clinically indicated.

 Graft-versus-Host Disease with Blood Transfusions: Transfusion-associated graft-versus-host disease has been observed rarely after transfusion of nonirradiated blood in patients treated with cladribine for non-MS treatment indications. In patients who require blood transfusion, irradiation of cellular blood components is recommended.

 Liver Injury: In clinical studies, 0.3% of MAVENCLAD-treated patients had liver injury (serious or causing treatment discontinuation) compared to 0 placebo patients. Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment. Discontinue MAVENCLAD if clinically significant liver injury is suspected.

 Hypersensitivity: If a hypersensitivity reaction is suspected, discontinue MAVENCLAD therapy. Do not use MAVENCLAD in patients with a history of hypersensitivity to cladribine. · Cardiac Failure: In clinical studies, one MAVENCLAD-treated patient experienced lifethreatening acute cardiac failure with myocarditis, which improved after approximately one week. Cases of cardiac failure have also been reported with parenteral cladribine used for

treatment indications other than multiple sclerosis. Instruct patients to seek medical advice if they experience symptoms of cardiac failure (e.g., shortness of breath, rapid or irregular

Adverse Reactions: The most common adverse reactions (incidence of >20%) are upper respiratory tract infection, headache, and lymphopenia.

Drug Interactions: Concomitant use with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short-term therapy with corticosteroids can be administered. Monitor for additive effects on the hematological profile with use of hemotoxic drugs. Avoid concomitant use of antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.

Use in Specific Populations: Studies have not been performed in pediatric, or elderly patients >65 years, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.

To report SUSPECTED ADVERSE REACTIONS, contact EMD Serono, Inc. at 1-800-283-8088 ext. 5563

or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.

All graphics used herein are for illustrative purposes only.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Conada.

MAVENCLAD and MS LifeLines are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.

MS LifeLines Pro is a trademark of Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono, Inc., One Technology Place, Rockland, MA 02370

This website is intended for U.S. healthcare professionals only.

Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

CONTACT US | PRIVACY POLICY | TERMS & CONDITIONS | SITE MAP | CHAT WITH MEDICAL AFFAIRS | COOKIE SETTINGS